Teva Pharmaceutical Industries Ltd.

Global Generic Medicines

September 9, 2016

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This presentation contains forward-looking statements, which are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a generic version); our ability to integrate the acquisition of Allergan plc's worldwide generic pharmaceuticals business ("Actavis Generics") and to realize the anticipated benefits of such acquisition (and the timing of realizing such benefits); the fact that following the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt incurred to finance the Actavis Generics acquisition; the fact that for a period of time following the consummation of the Actavis Generics acquisition, we will have significantly less cash on hand than previously, which could adversely affect our ability to grow; ; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information, whether as a result of new information, future events or otherwise.

Agenda

Opening —	Erez Vigodman
Intro Global Generics —	Siggi Olafsson
North America —	Andy Boyer
Europe —	Dipankar Bhattacharjee
Growth Markets —	Erez Israeli
Generic R&D —	Hafrun Fridriksdottir
Portfolio & Pipeline —	Daniel Motto
Wrap Up —	Siggi Olafsson

EREZ VIGODMAN

President & CEO
Teva Pharmaceutical Industries Ltd.

SIGGI OLAFSSON

Global Generic Medicines

Teva Global Generic Medicines – by the numbers

$14-15 BILLION IN ANNUAL SALES NOT INCLUDING OTC	**16,500** EMPLOYEES	**80 MARKETS** WITH COMMERCIAL PRESENCE
16,000 PRODUCTS * IN GLOBAL PORTFOLIO	TOP 3 LEADERSHIP POSITION IN OVER **40 MARKETS**	**100+ MARKETS** WITH SALES
EXPANSIVE PIPELINE WITH **>300 FILES** PENDING AT FDA AND >2000 EX-US	**1,500 GENERIC PRODUCTS** LAUNCHES PLANNED GLOBALLY IN 2017	**120 BILLION** TABLETS, CAPSULES, INJECTABLES AND OTHER DOSAGE FORMS SOLD ANNUALLY

* Product = unique molecule or molecule combination, dosage form and country

Teva Global Generic Medicines team

SIGGI OLAFSSON
President & CEO Global Generic Medicines

Legacy Actavis
Legacy Teva



ANDY BOYER

North America



DIPANKAR BHATTACHARJEE

Europe



EREZ ISRAELI

Growth Markets



VALUR RAGNARSSON

Medis
Out-licensing

Commercial



HAFRUN FRIDRIKSDOTTIR

Generics R&D



DANIEL MOTTO

Portfolio & Business Development



EDRIC ENGERT

Biosimilars



HENRIETTE NIELSEN

Chief Transformational Officer

R&D / Portfolio / Innovation

Strong Leadership Team Leveraging Top Talent

Teva continues to lead the global generic market segment

Global generic market share* 2015 (worldwide, % of SUs)



#1 position worldwide by net sales and units

Significant gap to 2nd and 3rd tier players

Broad commercial coverage leverages largest generics R&D spend in the industry

* Based on IMS Health Generic Segment 2015, Standard Units (SU), non-adjusted except for divestitures

Global Generics – a promising growth outlook

Generic sales by region, 2015-2020, $ Billions



SOURCE: IMS Health, McKinsey

Markets trends and unmet needs – favors generics for the long-term

Urbanization



Governments struggle to deliver access to healthcare



Aging population



Changing middle class landscape



Increasing diagnosis/treatment rates



Generic medicines are a key part of the solution to rising healthcare costs

Manufacturing and development assets can be leveraged globally

The top companies can grow at or above market rates

Teva's winning formula for Generics

1. Top market position in key markets
   - Selective on where we play, and then achieve or maintain critical scale
2. Broad, diversified portfolio and industry leading R&D delivering pipeline of new opportunities
   - A constant flow of new products refreshes the portfolio, bringing value to patients, customers and payers
   - Differentiated products and technologies suffer less from price pressures
3. Competitive operational network, reliable supply and competitive costs
   - Make customer service the top priority
   - Continuously improve cost base and productivity - ongoing network optimization

Teva is best positioned to bring products from idea to market



Largest supplier of Active Pharmaceutical Ingredients	26 Development centers, more than 600 beds for clinical studies	68 finished dose facilities across 35 countries	Commercial presence in 80 countries	Acquiring Anda, 4th largest US distributor of generics

Teva's global footprint provides regional diversification

Global Generic Medicines
2016 Net Sales*



North America

#1 generic market position in largest global market

Broad portfolio and pipeline brings tremendous value to customers and patients

Europe

Top 3 position in 26 countries

Established infrastructure and sales force - requires minimal incremental investment

Growth Markets

Strong base with Japan JV, Russia/CIS, Asia Pacific & LatAm

Organic and inorganic growth opportunities

* Based on 2016 Full year estimate, excludes API Sales

Actavis Generics complements Teva's global reach



Strengthens Teva market position in key countries

- US, Canada, Russia, UK

New commercial presence in growth markets

- Asia Pacific - Thailand, Singapore

Opportunity to leverage pipeline in non-overlap countries

- Germany, Italy, France, Spain

* Based on IMS Health Generic Segment 2015, Standard Units

Focus on key growth drivers across each region

North America

- Continue leadership in first-to-files (FTFs)
- Maximize flexibility from US-based manufacturing and R&D resources
- Push the boundaries targeting complex products

Europe

- Leverage existing infrastructure and maximize value from market positon
- Strong pipeline with many first-to-market product opportunities
- Synergies with Specialty segment and Branded Generics

Growth Markets

- Build on solid base in key countries, supplement with acquisitions
- Expand into select markets
- Leverage Teva Generics & Specialty resources - customize pipeline and commercial model

OTC complements our business

Continues to be an appealing segment

PGT Joint Venture

- PG + Teva resources
- Global branding
- Top Brands:
  - Vicks
  - Swisse
  - ratiopharm/Teva (Company Branded Generics - CBG)

Regional Brands

- Legacy Actavis OTC
- $200M - $300M Sales
- Top products:
  - Sudocrem (UK)
  - Troxivan (Russia)
  - Decubal (Nordics)

US Private Label

- Teva + Actavis US OTC
- Gx Mucinex (with Perrigo)
- Confirmed first-to-file opportunities
  - Gx Nexium OTC
  - Gx Nicoderm CQ

Biosimiliars remain a strong fit within the Teva model

Best of both worlds

Positioning
Branding, promotion
Market access
GPO relations

Trade relations
Speed to market
Channel distribution
Medical



Teva biologic/biosimilar products today

GRANIX™ (TBO-FILGRASTIM) Injection

TevaGrastim

LONQUEX lipegfilgrastim

Eporatio®

ovaleap follitropin alfa

Industry leading R&D capabilities and portfolio delivering industry leading results

>2,000 new filings globally in 2015

Achieved almost half of US first-to-files in 2016

>500 active development projects

Internal CRO doses at least one phase 1 study every day in the last 12 months

The largest and most competitive fully integrated manufacturing and supply chain network in the industry…



- 68 Pharma sites
- 19 API sites
- 36 countries

Pricing pressures in Generics

Generic price erosion varies year-to-year

Companies are impacted differently

Chasing market share will destroy value

Teva's advantage:

- Price challenges are product specific - a broad diverse portfolio mitigates risk
- Strong understanding of the market
- Offering differentiated products – lower competition, durability
- Competitive cost position
- Industry leading pipeline – customers want access to our new products which brings them value

GDUFA goals at the FDA will benefit Teva's rich pipeline

Priority of First Generics

"For example, ***we consider "first generics" to be public health priorities****, as they can lead to increased patient access…..Under GDUFA, beginning in FY 2015, each of these* ***first generic submissions automatically receives a 15 month goal date****…. Because they are public health priorities, we expedite their review, like an express lane at the supermarket."*

- Janet Woodcock, M.D, Director of CDER at FDA

Teva has >300 files pending at the FDA majority are 1st - wave opportunities



ANDY BOYER

North America

Generics North America

NA market space

~5%	Generic retail market growth
$80bn	Generic retail net sales
~38%	Global Generic Market
>80%	Generic penetration



Teva's position

~50%	Of global generics business
18%	US Market share with clear leadership
300+	Filed products at the FDA
#1	Market position in US & Canada

Per internal data and MAT IMS

Teva is the indisputable leader in the US Generics marketplace



What does it mean to our customers?

- The broadest product portfolio covering 75% of US generic value
- Strongest pipeline across therapeutic categories
- Supply chain built to deliver superior service and competitive pricing

Best positioned organization to maximize greatest assets in the industry

* Based on IMS Health Generic Segment 2015, Standard Units

US purchasing power: Top 4 customers represent >85% of retail market*

Big-to-big relationships creates efficiency and win-win opportunities



Per internal data

US market continues to evolve
Teva is well-positioned to succeed in any new market dynamic

Market dynamics

- Supply chain disruptions and increased FDA scrutiny
- GDUFA shortened review time and reduced FDA backlog
- Price erosion is nothing new

Teva's position

- Teva operations is a competitive advantage and capable of creating additional value
- Allows Teva to maximize the value of the best R&D engine in the industry
- Diverse portfolio and competitive cost structure allows for long-term value creation

New US product launches – strong track record and even more compelling future



Expanded pipeline with 65 new filings in 2015

>300 files pending at the FDA

>100 confirmed first-to-files

North America – looking forward

- Combined two leading organizations that have all the ingredients required to grow and generate value
- Broadest in-line portfolio with the most promising pipeline
- Proven track record to maximize value of new product launches
- Portfolio and customer relationships to create win-win partnerships globally

DIPANKAR BHATTACHARJEE

Europe

Generics Europe

Europe market space

2.5%	Generics retail market growth
$24bn	Generics retail net sales
500m+	People in Europe
66%	Generics penetration but varies across countries



Teva's position

~25%	Of global generics business
~14%	Market share with clear leadership
272	Pipeline projects 2017 onwards
3	Integrated business lines (branded, Gx, OTC)

Per internal data and MAT IMS

Teva Generics Europe

Can create value if it has…

- Advantages of scale and top ranking in the key markets
- A rich and balanced pipeline
- Ability to adapt commercial strategies to different market constructs
- Lean and agile cost structure
- Leverage with other segments (i.e. OTC, specialty)

Teva today

- Top 3 market position in 26 Countries
- Unparalleled customer reach via a Generic sales force of ~2300
- Future launches covering 85% of patent expiries (till 2021) via strong pipeline of ~272 projects
- Strong talent base
- Integrated sales force and strategic wholesale & pharmacy channel management

Teva is the leader in Europe



- Teva and Actavis combination very complementary from product and geographical perspective especially in Eastern Europe
- Top position in largest EU generic pharma markets, leading to a top 3 generic position in 26 countries
- Addition of Actavis regional OTC business opening new areas of growth in UK and Nordics
- Commercial synergies actioned on a best of both between Teva and Actavis

Source: IMS and internal data

Our commercial strategy adapts to markets for high profitability

Europe net sales distribution by selling model



Market type	Example countries
INN (molecule name): Products selected based on price level and supply reliability	• United Kingdom • Netherlands • Denmark • Sweden • Norway
Pharmacy Driven: Substitution of prescribed brand in pharmacy, or script written as INN	• Ireland • France • Spain • Portugal • Italy
Physician Driven: Scripts written with brand names, limited substitution	• Poland • Czech Republic • Croatia • Baltic Region

The margin improvement is a result of a diligently executed transformation that will continue

Europe Generics operating profit evolution



How this was achieved

- Maintain leadership
- Focus on value through profitable growth rather than volume
- Optimized portfolio with robust tail management
- Robust pipeline and leadership in launches
- Lean and agile approach to commercial execution
- Strategic partnerships with global and regional customers

Key market highlights

UK



- #1 in the generics market
- Offers the widest range of generics, many with low competition
- Broad OTC portfolio including key brands such as Sudocrem

Germany



- #2 in the generics market
- ratiopharm leading brand in Germany
- Very successful hybrid OTC & generics business with increasing market share

Italy



- #1 in the generics market
- Double digit growth of operating profit
- Growing market share with new marketing approach towards physicians and pharmacies

Switzerland



- #1 in the generics market
- Double digit profit improvement due to portfolio optimization
- Among Teva highest ranking markets in profitability with ~40% market share

Bulgaria



- #1 in the generics market
- Actavis generics acquisition resulting in ~5 fold increase in revenues
- Addition of 2 new manufacturing plants in Dupnitsa & Troyan

Source: IMS and internal data

Generics Europe – looking forward

- Solidifying #1 position in Europe by increasing our share in highly profitable markets especially branded generics in Eastern Europe
- Executing integration plans and maximizing cost and revenue synergies
- Growing the Actavis brands in conjunction with existing Teva respiratory and women's health franchises
- Focus on delivering the launches of the newly combined pipeline
- Further leverage scale and breadth of business with regional and global customers

EREZ ISRAELI

Growth Markets

Growth Markets

Growth Markets space

8.2%	CAGR 2011-2015
74%	Spend on generics out of Rx market
6bn	People
50%	Of global GDP



Teva's position

~25%	Of global generics business
26	Operating Countries
1,194	Products in pipeline
3	Integrated business lines (branded, generic, OTC)

Per internal data and MAT IMS

Substantial opportunities for growth

Over $100bn incremental growth expected in Growth Markets by 2020

- Urbanization – 70% of global megacities are in Growth Markets
- Aging population – By 2050, older people in developing countries projected to increase significantly
- Middle Class – Asia expected to have 66% of the global middle class by 2030 vs 28% in 2009
- Governments struggle to deliver access to healthcare

Teva is well positioned to capitalize

- Established strong presence in selected markets
- Double digit growth over last three years
- Select inorganic moves in last 12 months (Actavis, Japan, Mexico)
- Leverage Teva strong capabilities and quality (R&D, portfolio, supply chain)

*Pro forma 2016 Generic estimate. World Population Ageing: 1950-2050 UN report. OECD/World Bank

Leveraging global Teva brand and capabilities enable working in all business models



Physician and retail driven markets with branded generics/OTC mix

Maturing, payer-physician mixed decision

Payers as gate-keepers consolidated distribution and providers*

Source: IMS; Internal analysis. * Excluding Japan

Key market highlights

Russia



- #3 in market
- Combined portfolio of almost 300 products and strong pipeline
- Significant commercial presence including 1,000 sales reps
- Continue to build strong Teva brand to maximize portfolio across OTC, branded genericsand Specialty

Japan



- #3 in the generic space
- JV with Takeda established in April, brings strong brand and reputation
- Broad portfolio of 775 products
- Significant commercial presence including ~350 sales reps
- Excellent relations with local authorities and distributors
- Capitalizing on Teva scale to improve supply chain competitiveness

Source: IMS and internal data

Key market highlights

Latin America

Active in the largest markets



Mexico - acquired Rimsa - strong player in private sector

Peru - #3 with strong commercial footprint in OTC and branded generics

Brazil - subscale, identified for inorganic move

Argentina - #9 with presence in branded generics and branded products

Chile - #1 with strong brand and commercial presence

Looking forward

- Leverage wide Teva-Actavis-Medis pipeline in retail space
- Continue to build strong Teva brand to expand portfolio across OTC, branded generics
- Look for partnerships or M&A in Brazil

Source: IMS and internal data

Teva Growth Markets – looking forward

- Executing integration plans in Japan, Mexico and Actavis markets to maximize sale and cost synergies
- Continue to build capabilities and competences at market level as response to market needs
- Look for compelling inorganic moves in the biggest untapped opportunities
- Continue to leverage Teva's global R&D efforts and invest in building a strong portfolio and pipeline for key markets

HAFRUN FRIDRIKSDOTTIR

Generics R&D

Establishing a global Generic R&D powerhouse

Combined two successful Generics R&D organizations

- Strong understanding of unique requirements for generic development
- Ability to deliver on aggressive timelines critical to generics
- Active in all therapeutic categories



Teva's Global Generics R&D

- 3000 employees
- 26 development sites
- 6 clinical sites

Teva Global Generic R&D network



- Ambernath, India
- Hafnarfjordur, Iceland
- Larne, N. Ireland
- Florida, USA
- New Jersey, USA
- Ulm, Germany
- Mumbai, India
- Mexico City, Mexico
- Munro, Argentina
- Kfar Saba, Israel
- Santiago, Chile
- Debrecen, Hungary
- New York, USA*
- Zagreb, Croatia

Oral Solids

- Nerviano, Italy
- Bucharest, Romania
- Zagreb, Croatia
- Godollo, Hungary
- Haarlem, Netherlands
- Runcorn, UK
- New York, USA*

Injectables

- Utah, USA
- Troyan, Bulgaria
- Larne, N. Ireland
- New York, USA*

Semi Solids, Transdermals & Liquids

- London, UK

Inhalation

- India (5 sites)
- Florida, USA

Clinics

- Harlow, UK
- Pennsylvania, USA
- New Jersey, USA
- Hafnarfjordur , Iceland
- Zagreb, Croatia
- Mumbai, India
- Sofia, Bulgaria

Main Regulatory Centers

*closing Feb. 2017

Teva & Actavis Development Complementary Capabilities

	Teva	Actavis
IR Oral Solids	✓	✓
ER Oral Solids	✓	✓
Semi-Solids & Liquids	✓	✓
Rings/Suppositories	✓	✓
Transdermals	✓	✓
Injectables	✓	✓
Complex Injectables	✓	✓
Biologics/Biosimilars	✓	NA
Inhalation	✓	✓
Ophthalmics	✓	✓

✓ Primarily Internal Capabilities

✓ Leveraging External Capabilities

Combined internal development capabilities have minimal gaps

Teva already has a proven track-record on complex products

Lidoderm Patch



Filed 2010
Exclusive FTF

Nuvaring Ring



Filed 2013
Excusive FTF

Abraxane Inj



Filed 2015
Excusive FTF

Suboxone Film



Filed 2012
Exclusive FTF

Butrans Patch



Filed 2013
Exclusive FTF

Forteo Inj

Filed 2015 Excusive FTF



and there is more to come…

Generic R&D 2015 performance

Country/Region	Count
United States	65
Europe (dossier completion)	65
Canada	22
Japan	17
Russia	14
New Project Total	**183**



65 new and existing dossiers resulted in around 1600 filings in 2015 in European countries and other markets that accept Europe dossiers

The US first-to-file performance was strong in 2015



*Unknown: Generic filer not yet identified (not sued). **NOTE**: Total is greater than 58 due to shared FTFs

Source: FDA Paragraph IV Certifications Website, IPD Analytics and internal analysis

And the momentum has been maintained in 2016



*Unknown: Generic filer not yet identified (not sued) Note: Total is greater than 27 FTFs due to shared FTFs

Source: FDA Paragraph IV Certifications Website, IPD Analytics and internal analysis

Generic R&D – looking forward

- Integration and optimization of the two R&D organizations
- Execute against continuous flow of new product opportunities
- Deliver on the high value products including complex products in respiratory, injectables, and other dosage forms
- Keep up the momentum - continue being the best of the best

DANIEL MOTTO

Portfolio Management

The outlook for new generic opportunities

The generic landscape

- Innovative companies continue to bring new medicines to market
- Patent challenges still bring value
- There are R&D synergies across regions, benefiting global generics companies with broad reach
- A company with the right assets and talented people can bring any product to market

There is no shortage of new generic product opportunities

Teva today – the strongest pipeline in the company's history

Where are we today?

- More files pending regulatory review than ever before
- >500 products in active development
- Broad diversified portfolio:
  - Regional diversity
  - Product-level diversity
  - Risk diversity

Well position to further expand the pipeline

- Robust future product opportunities
- Broad geographic coverage provides high ROI for R&D activities
- Significant internal development capabilities complemented with partnerships
- Strong, talented team that will deliver on future opportunities

Our combined capacity and budget for new projects has increased



The synergies will allow us to target more products

We can leverage our generics pipeline across multiple markets

Volume of combined company across regions for specific oral solids
2015, % of SUs



* Based on IMS Health Generic Segment 2015, Standard Units (SU), non-adjusted

Teva's US generic pipeline now exceeds 600 products



Sales value of targeted innovator products*

Filed products	$110 Billion
Confirmed Teva FTFs	$52 Billion
Other products	$58 Billion
In development	$90 Billion
Targeted innovator sales	**$200 Billion**

*Based on IMS Health June 2016 MAT

Our global pipeline has expanded significantly in the last year

	North America	Europe	Growth Markets
2015 filings*	87	1260	240
Total pending regulatory reviews	>375	>1,400	>600

Balanced Portfolio:

- Major products facing loss of exclusivity (the must-haves)
- Patent challenges to achieve early entry
- Local niche opportunities
- Branded Generics
- Complex/differentiated products

* Product filing = unique molecule or molecule combination, dosage form and Country

Our patent challenge activity leads the industry

- Product selection
- Development & filing
- Patent litigation
- Manufacturing
- Approval & launch

- > 90 active US Paragraph IV cases
- 2015-2016 YTD activity
  - 19 litigation wins
    Axiron (testosterone)
    Nuvaring (ee/etonogestrel)
    Beyaz (ee/drospirenone)
  - 25 settlements
    Revlamid (lenolidamide)
    Abilify (aripiprazole)
    Byetta (exenatide)
  - There were some losses…

FDA 2016 posting of first-to-files: we lead in both number and value



Source: FDA Paragraph IV Certifications Website as of August 4, 2016, IPD Analytics and internal analysis

Our extensive pipeline provides many near-term launch opportunities

2016/2017 FTF Launch Opportunities and 30 Month Stay Expirations

Ampyra®
Axiron®
Beyaz®
Butrans®
Byetta®
Contrave®
Effient®
Epzicom®
Letairis®
Livalo®
Mirvaso®
Neupro®
Nexium 24HR® OTC
Noxafil®
Nucynta®
Nucynta ER®
NuvaRing®
Onglyza®
Pennsaid 2%®
Qsymia®
Quillivant XR®
Reyataz®
Safyral®
Trokendi® 200mg
Tyvaso®
Uceris®
Viagra®
Viread®
Zohydro ER®
Zubsolv®

>30 first-to-file launch opportunities

>50 additional undisclosed or non-FTF product opportunities

Targeting >$30bn brand value

(***Red = Date Certain Launches)***

And we are securing a robust pipeline for the future

FTF Launch Opportunities and 30 Month Stay Expirations

2018

Abraxane®
Abstral®
Acanya®
Aptensio XR®
Bunavail®
Dificid®
Forteo®
Flector®
Gilenya®
Ilevro®
Izba®
Jadenu®
Latuda®
Moviprep®
Pazeo®
Pradaxa®
Orenitram®
Quillichew ER®
Relistor®
Rytary®
Sancuso®
Solodyn®
Tradjenta®
Ulesfia®
Viibyrd®
Vesicare®
Xifaxan®
Zytiga®

(Red = Date Certain Launches)

2019 and beyond

Absorica®
Adzenys XR-ODT®
Brilinta®
Chantix®
Folotyn®
Gralise®
Janumet®
Januvia®
Osmoprep®
Picato®
Rayos®
Revlimid®
Rozerem®
Silenor®
Zipsor®
Zyclara®

Confidential Settlements/ Cases Dismissed

Epiduo®
Pataday®
Pristiq®
Vigamox®
Xopenex® HFA
Astagraph XL®
Embeda®
Levitra®
Atripla®
Clindesse®
Diclegis®
Exjade®
Fosrenol®
Prezista®
Tarceva®
Truvada®

70 first-to-file launch opportunities

150 + additional undisclosed or non-FTF product opportunities

Targeting >$70bn brand value*

*Based on IMS Health June 2016 MAT

Teva portfolio & pipeline – looking forward

- Integration of our pipeline and in-market portfolio overlaps
  - Proceed ahead with the most advanced development programs
  - Switch to the most reliable, cost effective supply sources (internal & external)

- Ongoing new product selection and revisit past ‘no go’ decisions
  - Greater capacity for high-cost or high-risk projects
  - Ability to target smaller, niche opportunities

- Fully utilize expanded pipeline across markets

- Prioritization of key opportunities

SIGGI OLAFSSON

Global Generic Medicines

Global Generic Medicines looking forward

